BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

WuXi AppTec's Changzhou Facility Gains PMDA Approval, Bolstering Global Expansion Plans

Latest regulatory approval follows on the back of expansion plans announced during DCAT 2024 With peptides, oligos and peptide conjugates continui...

April 22, 2024 | News

Invenra and Catalent Forge Partnership to Advance Cancer Treatment Innovations

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Dev...

April 03, 2024 | News

Aragen Biologics Launches First Phase of New Facility in India, Spearheading Novel Anticancer mAb Manufacturing

Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, announced that it has operat...

March 28, 2024 | News

WuXi Biologics Breaks Ground on State-of-the-Art $1.4 Billion CRDMO Facility in Singapore

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced ...

March 19, 2024 | News

Suven Pharmaceuticals Joins Forces with Cohance Lifesciences in Transformative Merger to Strengthen CDMO Dominance

Transformative Merger with 2x Scale and Double-Digit EPS Accretion in the first year Suven poised to become a leading integrated CDMO player...

March 01, 2024 | News

BioCina and NovaCina Join Forces for Integrated Biologics Solutions

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish...

February 28, 2024 | News

GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj

Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use in South Korea as an adjuvant cell th...

February 27, 2024 | News

CATUG and Crystal Bio Launch Joint Lab for Advanced Nucleic Acid Analysis

CATUG, a distinguished global entity specializing in integrated nucleic acid and drug delivery CRDMO services, is combining capabilities with Crystal ...

February 25, 2024 | News

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Dr...

February 21, 2024 | News

Samsung Biologics and LegoChem Biosciences Forge Strategic Partnership for ADC Development and Manufacturing

The collaboration marks a pivotal milestone as Samsung Biologics commits to providing cutting-edge antibody development and drug substance manufact...

February 12, 2024 | News

Novo Nordisk's Investment Arm, Novo Holdings, Seals $16.5 Billion Deal to Acquire Catalent in All-Cash Transaction

Catalent, Inc. (NYSE: CTLT), a prominent player in advancing global patient treatment solutions, and Novo Holdings, a holding and investment entity oversee...

February 06, 2024 | News

WuXi Biologics Achieves Milestone with 16,000L Manufacturing Run in Ireland

First manufacturing run successful for MFG7 facility at the Ireland site Largest manufacturing scale to date achieved by combining four 4,000-liter sing...

February 01, 2024 | News

WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development

WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...

January 31, 2024 | News

WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...

January 24, 2024 | News

Stay Connected